<DOC>
	<DOCNO>NCT00104273</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , efficacy two dose level rasagiline mesylate versus placebo patient mild-to-moderate Alzheimer 's Disease take Aricept .</brief_summary>
	<brief_title>Rasagiline 1 mg 2 mg Added Aricept 10 mg Daily Patients With Mild Moderate Alzheimer 's Disease ( AD )</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>1 . Age range : Adult patient , 45 90 year age inclusive . 2 . Gender distribution : men woman . Women childbearing potential ( &lt; 1 year postmenopausal ) must practice effective contraception negative serum bhCG Screening . 3 . Diagnosis : diagnostic evidence probable Alzheimer 's Disease consistent DSMIV 290.00 290.10 NINCDS ADRDA criterion . This evidence may compile Screening must fully document patient 's study file Baseline visit . 4 . Stable Aricept® dose 10 mg daily &gt; = 8 week . 5 . Head image ( CT MRI ) : evidence focal disease account dementia head image ( CT MRI ) obtain within 12 month prior Baseline . If head image obtain prior Screening , head MRI obtain part Screening evaluation ; MRI also use Baseline volumetric analysis . The Baseline MRI obtain volumetric analysis must also show evidence focal disease account dementia . 6 . Degree dementia : MMSE score &gt; = 15 &lt; = 26 Screening Baseline . 7 . Race ethnicity : race ethnic group . 8 . Health : generally healthy ambulatory ambulatoryaided ( i.e. , walker cane ) . Corrected vision hear sufficient compliance testing procedure . 9 . Clinical laboratory value must within normal limit , abnormal , must judge clinically insignificant Investigator . 10 . Patients vitamin B12 deficiency stable dose medication least 12 week prior Screening normal serum vitamin B12 level Screening eligible . This stable dose vitamin B12 must maintain throughout study . Subjects might otherwise eligible rescreened Vitamin B12 Baseline . 11 . Patients hypothyroidism stable dose medication least 12 week prior Screening , normal TSH free T4 screening , consider euthyroid eligible . This stable dose must maintain throughout study . 12 . Patients must caregiver daily contact patient ( e.g. , average 10 hour per week ) , observe possible adverse event , accompany patient visit . 13 . Patients must sufficiently fluent English capable reliably complete study assessment . 1 . Patients take ( ) Aricept® dose 10 mg daily ( 10 mg &lt; 8 week ) ; ( b ) medication Alzheimer 's Disease except stable , prescribed dose 20 mg daily memantine least 4 week ( precede titration 20 mg daily ) . 2 . No reliable caregiver . 3 . Neurological disorder affect cognition ability assess associate Alzheimer 's Disease , Parkinson 's disease , multiinfarct dementia , dementia due cerebrovascular disease , Huntington 's disease , Pick 's disease , CreutzfeldJacob disease , Lewy Body disease , normal pressure hydrocephalus , brain tumor , progressive supranuclear palsy , seizure disorder , subdural hematoma , multiple sclerosis , well patient human immunodeficiency virus ( HIV ) disease , neurosyphilis , history significant head trauma follow persistent neurological deficit know structural brain abnormality . 4 . Psychiatric disorder affect ability ass cognition schizophrenia , bipolar unipolar depression , sleep disorder . 5 . Dementia complicate organic disease Alzheimer 's Disease delusion ( DSM 290.20 290.12 ) , delirium ( DSM 290.30 290.11 ) , depression ( DSM 290.21 290.13 ) . 6 . Drug alcohol abuse dependence &lt; = 5 year DSM IV criterion . 7 . Any active clinically significant condition affect absorption , distribution , metabolism study medication ( e.g. , inflammatory bowel disease , gastric duodenal ulcer , hepatic disease , severe lactose intolerance ) . 8 . Uncontrolled hypertension ( sit systolic &gt; = 160 mmHg and/or diastolic &gt; = 95 mmHg ) assess Investigator regardless whether patient take antihypertensive medication . 9 . Insulindependent diabetes diabetes stabilize diet and/or oral hypoglycemic agent demonstrate Hb A1c &gt; 8.0 % random serum glucose value &gt; 170 mg/dL . 10 . Evidence clinically significant , active gastrointestinal , renal , hepatic , respiratory , endocrine , cardiovascular system disease . Patients right bundle branch block ( complete partial ) may include study , patient leave bundle branch block exclude . 11 . History malignant neoplasm ( include basal squamous cell carcinoma skin ) treat within 5 year prior study entry , current evidence malignant neoplasm , recurrent , metastatic disease , major risk factor malignant melanoma ( xeroderma pigmentosum , personal history melanoma , 100 mole , puva radiotherapy . 12 . Donation blood blood product 30 day prior Screening plan donate blood participate study within 30 day completion study . 13 . Women pregnant breastfeeding . 14 . Patients and/or caregiver unwilling unable fulfill requirement study . 15 . Known hypersensitivity cholinesterase inhibitor MAO MAOB inhibitor . 16 . Use unapproved prior concomitant medication , include : Recent ( &lt; = 12 week ) concomitant use MAO inhibitor . Recent ( &lt; = 6 week ) concomitant use SSRIs . ( SSRIs tricyclic tetracyclic antidepressant low dos permissible , follow : citalopram &lt; = 20 mg daily , escitalopram &lt; = 10 mg daily , sertraline 25100 mg daily ) . Recent ( &lt; = 1 week ) concomitant use sympathomimetics ( include ephedra supplement ) . Recent ( &lt; = 1 week ) concomitant use meperidine . Recent ( &lt; = 1 week ) concomitant use dextromethorphan . Recent ( &lt; = 1 week ) concomitant use gentamicin . 17 . Any condition would make patient caregiver , opinion Investigator , unsuitable study . 18 . Involvement investigational trial precede 3 month likely involvement investigational trial course study . 19 . Contraindications MRI scanning , include CNS aneurysm clip , implanted neural stimulators , implanted cardiac pacemaker defibrillator , cochlear implant , metallic ocular foreign body , insulin pump , metal shrapnel bullet .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Dementia , Alzheimer 's Disease</keyword>
</DOC>